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Background: An early age at Breast Cancer (BC) onset may be a hallmark of inherited predisposition, but BRCA1/2
mutations are only found in a minority of younger BC patients. Among the others, a fraction may carry mutations
in rarer BC genes, such as TP53, STK11, CDH1 and PTEN. As the identification of women harboring such mutations
allows for targeted risk-management, the knowledge of associated manifestations and an accurate clinical and
family history evaluation are warranted.
Case presentation: We describe the case of a woman who developed an infiltrating ductal carcinoma of the right
breast at the age of 32, a contralateral BC at age 36 and another BC of the right breast at 40. When she was
39 years-old, during a dermatological examination, mucocutaneous features suggestive of Cowden Syndrome, a
disorder associated to germ-line PTEN mutations, were noticed. PTEN genetic testing revealed the novel c.71A > T
(p.Asp24Val) mutation, whose deleterious effect, suggested by conservation data and in silico tools, was definitely
demonstrated by the incapacity of mutant PTEN to inhibit Akt phosphorylation when used to complement
PTEN-null cells. In BC tissue, despite the absence of LOH or somatic mutations of PTEN, Akt phosphorylation was
markedly increased in comparison to normal tissue, thus implying additional somatic events into the deregulation
of the PI3K/Akt/mTOR pathway and, presumably, into carcinogenesis. Hence, known oncogenic mutations in PIK3CA
(exons 10 and 21) and AKT1 (exon 2) were screened in tumor DNA with negative results, which suggests that the
responsible somatic event(s) is a different, uncommon one.
Conclusion: This case stresses the importance of clinical/genetic assessment of early-onset BC patients in order to
identify mutation carriers, who are at high risk of new events, so requiring tailored management. Moreover, it
revealed a novel PTEN mutation with pathogenic effect, pointing out, however, the need for further efforts to
elucidate the molecular steps of PTEN-associated carcinogenesis.
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A young age at Breast Cancer (BC) onset may be a hall-
mark feature of inherited predisposition. Indeed, germ-line
mutations in the two major BC genes BRCA1 and BRCA2
have been reported in 15 to 23% of younger Italian BC pa-
tients [1,2], consistently with frequencies described in other
western populations, which range from 6 to 23% [3-5].
Although the majority of the remaining cases might be
explained by a multifactorial etiology, mutations in rarer
BC predisposing genes should also be considered. Rare,* Correspondence: daniela.turchetti@unibo.it
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reproduction in any medium, provided the orhigh penetrance BC genes include TP53, STK11, CDH1
and PTEN. Collectively, they are generally thought to ac-
count for less than 1% of inherited BC; nevertheless, an
accurate clinical and family history evaluation may provide
significant clues to the identification of patients carrying
such uncommon mutations. Recognizing mutation car-
riers is crucial to plan targeted risk-management accord-
ing to the specific gene, as is routinely done for BRCA
mutation carriers.
The PTEN gene encodes a negative regulator of the
PI3K/Akt/mTOR pathway and is one of the most fre-
quently mutated genes in cancer, with loss of heterozygos-
ity at the PTEN locus being reported in about 40% of
invasive BC [6,7]. Conversely, germ-line PTEN mutationsl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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manifestations that are collectively labeled PTEN Hamar-
toma Tumor Syndrome (PHTS). The prototypic syndrome,
Cowden Syndrome (CS), is featured by macrocephaly,
gastrointestinal lesions and cerebellar gangliocytoma, as
well as by benign and malignant tumors of the thyroid,
the endometrium and the breast, with a lifetime risk of BC
estimated to be as high as 85.2% [8]. Nevertheless, the
most typical features are specific mucocutaneous lesions,
which include trichilemmomas, acral keratoses and oral
papillomatous papules, and occur in 90-100% of cases.
Here we describe a patient with early-onset, metachro-
nous bilateral BC, who presented with mucocutaneous
features suggesting CS and was found to carry a novel
missense PTEN mutation. Functional assessment of the




An Italian woman underwent lumpectomy of the right
breast with axillary dissection at the age of 32 years for
Invasive Ductal Carcinoma at stage pT2N1a(1/35)M0. The
tumor was ER and PR positive (both 90%) and HER2/neu
negative. She received postoperative radiotherapy, chemo-
therapy (Epirubicin plus CMF) and Tamoxifen. Four years
later, at the age of 36, she was diagnosed with contralateral
breast cancer and total left mastectomy was performed.
Pathologic examination revealed a Invasive Ductal Carcin-
oma (0.12 cm in diameter) in a context of Ductal Carcin-
oma In Situ of cribriform and micropapillary type. Sentinel
lymph node was negative; ER and PR expression positive
(90% and 40%, respectively), HER2/neu negative. She was
prescribed endocrine treatment with LHRH agonist and
anastrozole.
When she was 39 years-old, during a dermatological
examination, mucocutaneous features suggestive of CS
were noticed (Figure 1). The patient was therefore referred
to the genetic clinic: family history was unremarkable,
whereas previous clinical manifestations in the patientFigure 1 Cutaneous findings of our case. A and B) Palmoplantar kerato
papules lesions that occur as asymptomatic erythematous grouped vesicle
the nose E) Multiple small papules on the gingiva with cobblestone appeawere also consistent with CS; indeed, at the age of 28 she
underwent thyroidectomy for goiter and at 31 she had a
uterine leyomioma removed; she also had several skin le-
sions removed, such as lymphangiomata of the trunk, lip-
omas, keratoses. In addition, clinical examination revealed
macrocephaly (head circumference: 61 cm). The diagnosis
of CS was therefore confirmed according to the criteria of
the National Comprehensive Cancer Network (http://www.
nccn.org), and proper surveillance recommended [8].
At the age of 40, another tumor was detected at the
right breast, consisting of a multicentric Invasive Ductal
Carcinoma rypT1c(m) with negative ER/PR and positive
HER2/neu (80%). After total right mastectomy was per-
formed, adjuvant chemotherapy with Paclitaxel and
Trastuzumab was undertaken, which, however, was dis-
continued after 3 months due to the occurrence of inter-
stitial pneumonia. Pulmonary function was promptly
recovered after treatment discontinuation and steroids ad-
ministration, and the patient is currently disease-free after
30 months.
Gene testing
The mutational analysis of PTEN was performed by se-
quencing all 9 exons of the gene, as well as the splice-
junctions and the gene promoter region, in DNA extracted
from peripheral lymphocytes of the patient, after informed
consent was collected and blood sample obtained.
The analysis revealed the heterozygous transversion
c.71A > T in exon 1 (RefSeq NG_007466), predicting the
substitution of a residue of aspartic acid with a valine at
codon 24 (p.Asp24Val) (Figure 2A). To our knowledge, this
mutation had not been reported before; in addition, it was
absent in the database of pathogenic mutations Human
Gene Mutation Database-HGMD (http://www.hgmd.cf.ac.
uk/ac/index.php/) and was neither reported in the Exome
Variant Server (http://evs.gs.washington.edu/EVS/), nor in
the 1000 genomes browser (http://browser.1000genomes.
org/index.html). Furthermore, 96 controls from the same
geographical area of the patient were screened for the mu-
tation, without finding any carrier. The analysis performedsis; C) Multiple seborrheic Keratoses and benign lymphangiomatosis
















Figure 2 Genetic and molecular characterization of PTEN c.71A>T mutation. A) Electropherogram showing PTEN c.71A > T transversion;
B) PTEN amino acidic sequence alignment among species: H.sapiens [HS], P.troglodytes [PT], M.mulatta [MM], C.lupus [CLP], B.taurus [BT], M.
musculus [MusM], R.norvegicus [RN], G.gallus [GG], X.laevis [XL], D.rerio [DR], D.melanogaster [DM] and A.gambiae [AG]; C) Western Blot analysis on
total cell lysates of XTC.UC1 cells tranfected with wild type PTEN [WT], PTENAsp24Val, PTENAsn48Lys, on Empty Vector [EV], and on untransfected XTC.
UC1 cells, showing that only PTEN WT is able to inhibit P-AktSer473, P-AktThr308 and P-S6RP; D) Immunohistochemical analyses of the breast tumors
[Magnification 200X]: Phospho-AKT-Ser473 immunostaining, showing negative reaction in normal breast duct (a), strong nuclear and cytoplasmic
immunoreactivity in infiltrating (b) and in situ (c) breast tumors; PTEN immunostaining, showing normal reaction in normal duct (d) and in breast
infiltrating and in situ carcinomas (e, f).
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from HomoloGene (http://www.ncbi.nlm.nih.gov/homolo-
gene) and multialigned with MUSCLE (http://www.ebi.ac.
uk/Tools/msa/muscle/) showed that Asp24 is highly con-
served among metazoans (Figure 2B); accordingly, the in
silico tools SIFT and Polyphen2 predicted a deleterious ef-
fect of the variant, with scores of 0 and 0.942, respectively.
Functional assessment of the mutation
PTEN full length cDNA was cloned in a pCDNA 3.1(−)
(Invitrogen, Life Technologies Ltd, UK) expression vec-
tor and site-directed mutagenesis was performed in
order to obtain the mutation under study (PTENAsp24Val)
and the known pathogenic mutation Asn48Lys (PTE-
NAsn48Lys) [9]. These mutant forms, as well as the wild-
type PTEN, were used to complement XTC.UC1 cells;XTC.UC1 is a cell line established from a metastasis of
thyroid oncocytic follicular carcinoma [10], which we
found to be null for PTEN (Additional file 1: Figure S1).
PTEN specific Western Blot analysis confirmed that
both the wild-type and the mutated proteins were
expressed; hence, their ability to regulate the PI3K/Akt/
mTOR pathway was investigated by assessing the relative
amount of the phosphorylated forms of AKT (at Ser473
and Thr308) and of the mTORC1 substrate 40S ribosomal
protein S6 (S6RP), in comparison to the respective total
counterparts. Only wild-type PTEN was found to inhibit
AKT and S6RP phosphorylation in complemented cells,
whereas PTENAsp24Val appeared, conversely, to lose PTEN
lipid phosphatase function, analogously to the PTE-
NAsn48Lys (Figure 2C). Thus, the p.Asp24Val mutation was
proven to be deleterious.
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Immunostaining was performed on paraffin-embedded,
formalin-fixed tissue of the first two breast tumors (right
IDC and left DCIS). PTEN was normally expressed in both,
with a sub-cellular distribution similar to the corresponding
normal breast tissue; conversely, p-AKT (Ser473) staining
showed a markedly increased AKT phosphorylation in the
tumors, compared to the normal tissue (Figure 2D), sug-
gesting that the PI3K/Akt/mTOR pathway is over-activated
in the tumor, unlike in normal tissue.
Screening of somatic mutations in PTEN, PI3KCA and AKT
Analysis of the PTEN coding sequence in the DNA ex-
tracted from the in situ breast carcinoma showed the
c.71A > T to be heterozygous, thus ruling out the loss of
the wild-type allele, and failed to detect any additional se-
quence variants. Recurrent oncogenic mutations in exon
10 and 21 of PI3KCA and exon 2 of AKT, which are
known to cause activation of the PI3K/Akt/mTOR path-
way in several cancer types, were also excluded by se-
quence analysis.Conclusions
Women harboring a predisposing gene mutation face a
high risk to develop BC at a young age and to experience
multiple primary BCs. These risks have been extensively
studied in women with BRCA1/2 mutations, whose aver-
age age at BC onset is around 45 years, while the risk of
contralateral BC 25 years after first BC is 47.4%, according
to recent figures [11].
For rarer conditions, such as CS, these risks and the
relative management are not so clearly established. Until
recently, lifetime BC risk in CS female patients was largely
accepted to be around 25-50%; however, recent reports on
two large series raised the estimated lifetime risk to 77-
85% [8,12]. Consistently, a pooled analysis of literature
data and records from the Mayo Clinic provided an esti-
mate of the cumulative BC risk as high as 81% [13]. The
age at BC onset is generally believed to be young (38–
50 years) [14]. Nevertheless, data on the risk for bilateral
BC are scarce; in the French series, out of 23 BC cases, 11
(48%) were reported as bilateral [12], while in the study by
Riegert-Johnson and colleagues 34% of patients diagnosed
with BC cancer had bilateral disease [13].
The case here reported adds evidence to the hypoth-
esis that PTEN mutation carriers are at high risk for
early-onset and multiple BCs, thus pointing out the need
to promptly identify these women in order to properly
manage such risks, similarly to BRCA carriers. To this
aim, it is crucial that clinicians caring for BC patients
are aware of associated manifestations suggesting rare
genetic syndromes, and/or that every patient with early-
onset BC is referred to cancer genetic assessment.Missense variants of uncertain significance are a rela-
tively common finding that complicates the interpretation
of gene test results. In our patient, we found the novel
missense mutation p.Asp24Val, which had not been re-
ported before. Anyway, different mutations at the same
codon had been described: the germ-line p.Asp24Tyr mu-
tation, in a Bannayan-Riley-Ruvalcaba patient [15], and
the p.Asp24Gly, detected in the germline of a CS patient
[16] as well as in sporadic tumors of the endometrium
and of the central nervous system as a somatic mutation
(COSM5170, http://www.sanger.ac.uk/genetics/CGP/cos-
mic/), supporting the functional relevance of the highly
conserved Asp24. These data, together with the in silico
prediction, strongly suggested a functional role of this
variant, which was confirmed by demonstrating in vitro
that the mutant PTEN, unlike the wild-type protein, was
unable to inhibit the PI3K/Akt/mTOR pathway.
Whether PTEN acts as a classical tumor suppressor
gene following Knudson’s two-hit hypothesis is still con-
troversial: on one hand, in a mouse model of prostate can-
cer, the complete loss of PTEN, unlike its dose-reduction,
was demonstrated to induce senescence instead of cancer,
unless the loss of TP53 co-occurred [17]. On the other
hand, PTEN immunostaining was proven to be negative
in 13 out of 15 BC samples from CS patients, suggesting
loss or inactivation of the wild-type PTEN allele in the
tumor [18]. To explain its heterogeneous behavior, PTEN
has been recently appointed as a haploinsufficient gene,
characterized, however, by tissue specificity and context
dependency [19].
In the present case, the mutation was demonstrated to
be at the heterozygous state in both normal and tumor tis-
sue and no additional PTEN sequence mutations were de-
tected in the tumor, which is in line with what we found
in non-breast tumors from other CS patients, where loss
or mutations of the wild-type PTEN allele were excluded.
In such cases, however, somatic mutations of different
genes were found, with an apparent correlation between
the specific gene and the type of tumor developed [20,21].
In the present case, the markedly increased Akt phosphor-
ylation detected in BC, if compared to normal tissue, led
us to infer that a somatic event had cooperated in deregu-
lating the PI3K/Akt/mTOR pathway and, presumably, in
inducing carcinogenesis. Hence, activating mutations
commonly found to impair PI3K/Akt/mTOR regulation in
cancer were analyzed in the breast tumor, with none of
them being detected. Such findings suggest the involve-
ment of a different, uncommon somatic event, such as the
possible epigenetic inactivation of the wild-type PTEN al-
lele (which could not be ruled out) or an unusual muta-
tion in genes involved in the PI3K/Akt/mTOR pathway,
thus demonstrating once again how carcinogenesis in
PTEN mutation carriers is a complex, still elusive process,
which requires major efforts to be elucidated.
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Additional file 1: Figure S1. PTEN-null status of XTC.UC1 cells. (A)
Electropherogram showing the hemizygous c.210delT within exon 4 of
the PTEN gene in XTC.UC1 cells compared to a wild-type control (lower
panel). The wild-type c.210delT is underlined. (B) Western blot for PTEN
confirming lack of the full-length protein in XTC.UC1 cells compared to a
control. Beta-actin was used as a loading control.Competing interests
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